Repeat Revascularization After Contemporary Percutaneous Coronary Intervention: An Evaluation of Staged, Target Lesion, and Other Unplanned Revascularization Procedures During the First Year
暂无分享,去创建一个
Michael J Pencina | Laura Mauri | David J Cohen | Neal S Kleiman | M. Pencina | L. Mauri | N. Kleiman | D. Cohen | D. Cutlip | K. Kennedy | Joshua M Stolker | Kevin F Kennedy | Jason B Lindsey | Donald E Cutlip | J. Stolker | Jason B. Lindsey | D. Cohen | Joshua M. Stolker | D. Cohen
[1] J. Klein,et al. Survival Analysis: Techniques for Censored and Truncated Data , 1997 .
[2] J. Marco,et al. Impact of restenosis and disease progression on clinical outcome after multivessel stenting in diabetic patients , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[3] H. Barnhart,et al. Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery Trial. , 2003, Medical science monitor : international medical journal of experimental and clinical research.
[4] M. Bourassa,et al. Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). , 2004, Journal of the American College of Cardiology.
[5] A. Schmermund,et al. Relationship Between Cardiovascular Risk as Predicted by Established Risk Scores Versus Plaque Progression as Measured by Serial Intravascular Ultrasound in Left Main Coronary Arteries , 2004, Circulation.
[6] D. Baim,et al. Beyond Restenosis: Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials , 2004, Circulation.
[7] S. Bergmann,et al. Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis, disease progression, and directed reintervention. , 2004, Journal of the American College of Cardiology.
[8] C. W. Barth,et al. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. , 2004, American heart journal.
[9] David J Cohen,et al. Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. , 2005, American heart journal.
[10] W. Laskey,et al. Clinical Progression of Incidental, Asymptomatic Lesions Discovered During Culprit Vessel Coronary Intervention , 2005, Circulation.
[11] Sunil V. Rao,et al. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). , 2006, The American journal of cardiology.
[12] M. Hong,et al. Safety of single versus multi-vessel angioplasty for patients with acute myocardial infarction and multi-vessel coronary artery disease: report from the New York State Angioplasty Registry , 2006, Coronary artery disease.
[13] David O. Williams,et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. , 2007, JAMA.
[14] Ralph D'Agostino,et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.
[15] J. Granada,et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. , 2007, JAMA.
[16] Brett G. Sylvia,et al. Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the ‘real world’ , 2008, Coronary artery disease.
[17] Deepak L. Bhatt,et al. Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. , 2008, American heart journal.
[18] R. Wilensky,et al. A comparison of bare-metal and drug-eluting stents for off-label indications. , 2008, The New England journal of medicine.
[19] P. Fitzgerald,et al. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. , 2008, American heart journal.
[20] P. Gurbel,et al. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. , 2008, American heart journal.
[21] D. Cohen,et al. Temporal Changes in Coronary Revascularization Procedures, Outcomes, and Costs in the Bare-Metal Stent and Drug-Eluting Stent Eras: Results From the US Medicare Program , 2009, Circulation.
[22] V. Novack,et al. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. , 2009, JACC. Cardiovascular interventions.
[23] M. Leon,et al. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events. , 2009, JACC. Cardiovascular interventions.
[24] U. Siebert,et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. , 2009, The New England journal of medicine.
[25] E. Hannan,et al. Safety and Efficacy of Drug-Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies , 2009, Circulation.
[26] D. Wagner,et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry. , 2009, Journal of the American College of Cardiology.
[27] J. Fajadet,et al. Impact of atherosclerotic disease progression on mid-term clinical outcome in diabetic patients in the drug-eluting stent era. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[28] G. Lemesle,et al. Incidence, predictors, and outcome of new, subsequent lesions treated with percutaneous coronary intervention in patients presenting with myocardial infarction. , 2009, The American journal of cardiology.
[29] Samin K. Sharma,et al. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. , 2010, JACC. Cardiovascular interventions.
[30] Christopher P Cannon,et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. , 2010, The New England journal of medicine.
[31] J. Messenger,et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. , 2010, Journal of the American College of Cardiology.
[32] Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200. , 2011, MMWR. Morbidity and mortality weekly report.
[33] Morbidity and Mortality Weekly Report , 2022 .
[34] Abigail Shefer,et al. Recommended Adult Immunization Schedule: United States, 2011* , 2011, Annals of Internal Medicine.
[35] Deborah A. Adams,et al. Summary of Notifiable Diseases - United States, 2011. , 2013, MMWR. Morbidity and mortality weekly report.